Raw authenticity can be disruptive in life sciences workplaces, but learning corporate fluency and stylistic pivots can help ...

Pushing boundaries, staying grounded, and having fun along the way are the key ingredients for success in biotech, writes ...

On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...

This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and ...

Single-domain antibodies (sdAbs), also known as NANOBODY® molecules, offer unique advantages in research and medicine, but their purification can be challenging due to limited affinity for Protein A.

Life sciences organizations invest heavily in marketing visibility. Most maintain a website, actively use LinkedIn, and participate in industry events. These efforts signal credibility, momentum, and ...

Artificial intelligence is reshaping life sciences, but deciding whether to build or buy AI solutions can be complex. This guide explores the critical factors behind each approach, helping ...

The FDA has approved the first oral GLP-1 treatment for obesity in the U.S.—Novo Nordisk’s Wegovy pill. This once-daily medication represents a major advancement in weight management, offering an ...

Small and mid-cap biotechs face a fundamental strategic choice that will determine their survival in this new world of business. How will they compete against well-capitalized incumbents while ...

On this episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big ...

Chris Smalley recently retired from Merck, where he had responsibility for innovative implementation and validation, including single-use systems, globally. Previously, he was director of quality ...

A versatile portfolio of catalytic continuous reaction processes has been developed to meet the diverse needs of the chemical and pharmaceutical industries. By leveraging flow chemistry, these ...